Impact of Atrial Fibrosis Surface Area on the Occurrence of Atrial Fibrillation in Patients With Ischemic Stroke of Undetermined Origin: a Prospective Cardiac MRI Pilot Study.

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DIJON · Sep 14, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how the amount of scar tissue in the left atrium of the heart affects the risk of developing atrial fibrillation (AF) in patients who have had a stroke without a known cause. Atrial fibrillation is a condition that can lead to blood clots and increase the risk of another stroke. The researchers believe that using MRI imaging can help identify which patients would benefit from a special heart monitor that records their heart's rhythm over time. This might allow doctors to provide better care and reduce the number of patients who need this monitor.

To be eligible for the study, participants must be adults who have had a cryptogenic ischemic stroke (a stroke with no clear cause) within the last 30 days and are scheduled for the heart monitor implantation. They should also be in good health with a life expectancy of more than 12 months. Participants will receive a cardiac MRI within three months of their stroke, which involves using a special dye to create detailed images of their heart. This study is currently recruiting participants, and it's important to know that certain individuals, like those with specific health conditions or who cannot undergo MRI scans, are excluded from joining.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient who has provided free, written and informed consent
• • Patient of legal age
• • Patient with cryptogenic ischemic stroke within 30 days of inclusion, documented by brain imaging (cerebral angioscan or cerebral MRI)
• * Patients scheduled for implantable loop recorder implantation within 3 months of ischemic stroke in search of silent AF:
• • cryptogenic ischemic stroke or stroke with probable cardioembolic cause
• • no history of atrial fibrillation
• • no long-term anticoagulant therapy
• • with life expectancy \>12 months
• Exclusion Criteria:
• • Person not affiliated to national health insurance
• • Person under legal protection (curatorship, guardianship)
• • Person under court order
• • Pregnant, parturient or breast-feeding
• • Adult unable to give consent
• • Patient diagnosed with AF during stroke assessment
• * Patient with a contraindication to MRI or gadolinium injection:
• • Severe renal impairment (\<30ml/min Cockroft clearance due to gadolinium injection)
• • Claustrophobia / contraindication to MRI (metal implant not MRI compatible)
• • History of hypersensitivity to gadoteric acid or gadolinium-based contrast agents, and to meglumine
• • Uncontrolled asthma